Emicizumab (Hemlibra®, Roche, USA) is a bispecific humanized monoclonal antibody engineered to bring activated factor IX and factor X together allowing activation of factor X thus mimicking the action of missing FVIII in persons with hemophilia A (14). Here, F10 is linked to hemophilia A.